DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.

ABSTRACT:

Background

Chikungunya virus (CHIKV) causes outbreaks of chikungunya fever worldwide and represents an emerging pandemic threat. Vaccine development against CHIKV has proved challenging. Currently there is no approved vaccine or specific therapy for the disease.

Methods

To develop novel experimental CHIKV vaccine, we used novel immunization DNA (iDNA) infectious clone technology, which combines the advantages of DNA and live attenuated vaccines. Here we describe an iDNA vaccine composed of plasmid DNA that encode the full-length infectious genome of live attenuated CHIKV clone 181/25 downstream from a eukaryotic promoter. The iDNA approach was designed to initiate replication of live vaccine virus from the plasmid in vitro and in vivo.

Results

Experimental CHIKV iDNA

SUBMITTER: Tretyakova I 

PROVIDER: S-EPMC4038148 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature